Answers are grounded in this paper and cite their sources.
Demonstrates biomarker detection in ALS patients, indicating potential for clinical application.
CSF proteomics has emerged as a valuable strategy for identifying diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis (ALS). However, the limited availability and volumes of CSF samples restrict the broader clinical application of CSF-based biomarker panels. To address this challenge, we investigated whether the novel nucleic acid-linked immuno-sandwich assay (NULISA) multiplex platform—capable of quantifying multiple neural, glial, and inflammatory markers from minimal biofluid volumes—could validate previously proposed biomarkers and identify additional candidates relevant to ALS.
No takes yet. Share an insight, caveat, or question.
Baskar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: